TH
Thyrocare Technologies Ltd (THYROCARE)
₹456.30
Mkt cap
₹7,263 Cr
P/E ratio
41.50
P/B
13.11
Div yield
2.05%
ROE
28.40%
ROCE
35.40%
EPS (TTM)
₹11.00
Book value
₹35
52W range
343–662
Sector
Healthcare
Price history
Previous close
Thyrocare Technologies is engaged in the business of healthcare industry and is involved in providing quality diagnostic services at affordable costs to patients, laboratories and hospitals in India.
NSE THYROCAREBSE 539871
Health check
Constructive
ValuationFair
ProfitabilityStrong
GrowthModerate
TechnicalsNeutral
52-week range
−31.07% from high₹456
₹343+33.21% from low₹662
Current
₹456.30
Prev close
₹515.50
Day
−11.48%
Price performance
1D
−11.71%
1W
−1.73%
1M
−16.81%
3M
−23.05%
6M
+12.56%
1Y
+9.07%
YTD
−0.63%
Financials
Revenue, profit & margin
P/E ratio
41.5×
THYROCARE is 11% above the sector median of 37.4×
THYROCARE41.5×
Sector median37.4×
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 148 | 135 | 154 | 157 | 177 | 166 | 187 | 193 | 217 | 196 | 224 | 240 | 271 | |
| Expenses | 110 | 103 | 121 | 115 | 129 | 124 | 130 | 135 | 145 | 138 | 149 | 163 | 182 | |
| Operating Profit | 38 | 32 | 34 | 42 | 48 | 42 | 57 | 58 | 71 | 58 | 75 | 77 | 89 | |
| OPM % | 25% | 23% | 22% | 27% | 27% | 25% | 30% | 30% | 33% | 30% | 34% | 32% | 33% | |
| Other Income | 3 | 3 | 3 | 4 | 3 | 4 | 5 | 5 | 3 | -1 | 5 | 5 | -41 | |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | -0 | 2 | 1 | 2 | |
| Depreciation | 11 | 13 | 13 | 11 | 13 | 17 | 14 | 11 | 12 | 22 | 14 | 12 | 14 | |
| Profit before tax | 28 | 20 | 23 | 34 | 37 | 28 | 47 | 50 | 63 | 35 | 64 | 68 | 34 | |
| Tax % | 28% | 26% | 25% | 29% | 28% | 32% | 54% | 24% | 24% | 21% | 24% | 25% | 55% | |
| Net Profit | 20 | 15 | 17 | 24 | 26 | 19 | 22 | 38 | 48 | 28 | 49 | 51 | 15 | |
| EPS in Rs | 1.28 | 0.97 | 1.12 | 1.52 | 1.68 | 1.20 | 1.36 | 2.45 | 3.02 | 1.82 | 2.96 | 3.28 | 1.00 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Sep 202651.02%Promoter
Promoters51.02%9.90
FIIs9.37%3.94
DIIs25.92%5.00
Public13.69%0.98
Ownership trend
Peers
7 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Dr Lal Pathlabs | ₹1,906.40 | 56.91 | 31,999 | 0.73% | 171 | +28.02% | 798 | +19.10% | 28.00% |
| Vijaya Diagnost. | ₹1,445.70 | 79.42 | 14,890 | 0.14% | 53 | +37.60% | 231 | +22.83% | 20.53% |
| Metropolis Healt | ₹545.65 | 54.39 | 11,320 | 0.37% | 57 | +25.77% | 450 | +16.62% | 17.81% |
| Thyrocare Tech. | ₹456.30 | 41.46 | 7,263 | 2.05% | 15 | −11.56% | 271 | +25.07% | 35.38% |
| Nephrocare Health Services | ₹614.55 | 72.61 | 6,180 | 0.00% | 32 | +34.89% | 282 | +23.69% | 15.34% |
| Suraksha Diagno. | ₹316.35 | 46.02 | 1,648 | 0.16% | 13 | +38.40% | 88 | +20.75% | 17.29% |
| Krsnaa Diagnost. | ₹503.75 | 16.52 | 1,634 | 0.40% | 16 | −19.12% | 211 | +19.95% | 12.71% |
| Median: 16 Co. | ₹377.58 | 37.37 | 1,016 | 0.07% | 13 | +25.77% | 103 | +19.10% | 21.90% |
Filings
Annual reports11
Concall transcripts69
PPTOct 2026RECOct 2026TranscriptJul 2026PPTJul 2026RECJul 2026TranscriptMay 2026PPTMay 2026TranscriptFeb 2026PPTFeb 2026RECFeb 2026TranscriptOct 2025PPTOct 2025TranscriptJul 2025PPTJul 2025RECJul 2025TranscriptApr 2025PPTApr 2025RECApr 2025TranscriptJan 2025PPTJan 2025TranscriptOct 2024PPTOct 2024TranscriptJul 2024PPTJul 2024
Announcements5
Execution Of Share Purchase Agreement In Relation To The Sale Of The Company'S Entire Shareholding In Nueclear Healthcare Limited, A Wholly Owned Subsidiary Of The Company 30 Oct - Thyrocare signed SPA on Oct 30, 2026 to sell 100% of Nueclear Healthcare for about Rs.141.4 crore.Announcement under Regulation 30 (LODR)-Newspaper Publication 30 Oct - Please find attached herewith Newspaper Publication of Unaudited Financial Results for the quarter and half year ended on September 30, 2026Shareholder Meeting / Postal Ballot-Scrutinizer"s Report 29 Oct - Postal ballot approved purchase of land/building and sale of entire Nueclear Healthcare stake to Trovera.Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot 29 Oct - Postal ballot approved land purchase and sale of Nueclear Healthcare stake on October 29, 2026.Audio Recording Of Earnings Conference Call For The Quarter And Half Year Ended September 30, 2026 29 Oct - Audio recording of post-results earnings call for Q2 and H1 FY2026 available on website.